Warm contrast dye during ERCP for bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether using a warm (37°C) non-ionic contrast agent (a dye used during ERCP) is better than standard dye for people with hilar cholangiocarcinoma. The goal is to see if it reduces complications and improves outcomes during the procedure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of hilar cholangiocarcinoma (a type of bile duct cancer at the liver's exit).
- You must be between 18 and 90 years old.
- You must be having or have just had an ERCP (a scope procedure to look at and treat the bile ducts).
- You cannot have had an ERCP before this one.
- You cannot have certain serious conditions, like bleeding problems, acute pancreatitis, or a prior surgery that changed your stomach or bile duct anatomy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a new way to detect bile duct cancer (cholangiocarcinoma) using samples taken during a routine ERCP. It tests a special protein marker that might help doctors diagnose the condition more accurately.
This trial tests a special scope that helps doctors see inside the bile duct during an ERCP procedure. It may help people with blocked bile ducts that can't be treated with standard methods.
This study compares two procedures to drain bile from the liver in people with blocked bile ducts caused by cancer that cannot be removed. It looks at whether using an ultrasound-guided approach along with standard ERCP works better than ERCP alone.
This trial tests a combination of heat therapy inside the bile duct (endobiliary RFA) with immunotherapy (durvalumab) and chemotherapy (gemcitabine and cisplatin) for people with unresectable extrahepatic cholangiocarcinoma. The goal is to see if adding the heat treatment improves outcomes.
This study compares two different devices used during a procedure called ERCP to look at and take samples from a narrowed bile duct. The goal is to see which one is better at helping doctors diagnose the cause of the narrowing.
This trial tests whether treating hilar bile duct cancer with either radiofrequency ablation (heat) or photodynamic therapy (light-activated medicine) can help patients when surgery isn’t an option. It aims to treat the tumor directly without planned surgery soon.
Hear when a new Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.